Developmental dynamics of voltage-gated sodium channel isoform expression in the human and mouse neocortex

Lindsay Liang¹, Siavash Fazel Darbandi¹, Sirisha Pochareddy², Forrest O. Gulden², Michael C. Gilson¹, Brooke K. Sheppard¹, Atehsa Sahagun³, Joon-Yong An⁴, Donna M. Werling⁵, John L.R. Rubenstein¹, Nenad Šestan^{2,6,7,8,9}, Kevin J. Bender³, and Stephan J. Sanders^{1,10,11,†}

¹Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158.

²Department of Neuroscience and Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA.

³Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.

⁴School of Biosystem and Biomedical Science, College of Health Science, Korea University, Seoul, 02841, Republic of Korea.

⁵Laboratory of Genetics, University of Wisconsin-Madison, Madison, WI 53706, USA.

⁶Program in Cellular Neuroscience, Neurodegeneration, and Repair and Yale Child Study Center, Yale School of Medicine, New Haven, CT 06510, USA.

⁷Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06520, USA.

⁸Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA.

⁹Department of Comparative Medicine, Program in Integrative Cell Signaling and Neurobiology of Metabolism, Yale School of Medicine, New Haven, CT 06510, USA.

¹⁰Institute for Human Genetics, University of California, San Francisco, San Francisco, CA 94158, USA.

¹¹Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA.

[†]Please address correspondence to: stephan.sanders@ucsf.edu (S.J.S.)

Abstract

Objective: Genetic variants in the voltage-gated sodium channels *SCN1A*, *SCN2A*, *SCN3A*, and *SCN8A* are leading causes of epilepsy, developmental delay, and autism spectrum disorder. The mRNA splicing patterns of all four genes vary across development in the rodent brain, including mutually exclusive copies of the fifth protein-coding exon detected in the neonate (5N) and adult (5A). A second pair of mutually exclusive exons is reported in *SCN8A* only (18N and 18A). We aimed to quantify the expression of individual exons in the developing human neocortex.

Methods: RNA-seq data from 176 human dorsolateral prefrontal cortex samples across development were analyzed to estimate exon-level expression. Developmental changes in exon utilization were validated by assessing intron splicing. Exon expression was also estimated in RNA-seq data from 58 developing mouse neocortical samples.

Results: In the mature human neocortex, exon 5A is consistently expressed at least 4-fold higher than exon 5N in all four genes. For *SCN2A*, *SCN3A*, and *SCN8A* a synchronized 5N/5A transition occurs between 24 post-conceptual weeks (2nd trimester) and six years of age. In mice, the equivalent 5N/5A transition begins at or before embryonic day 15.5. In *SCN8A*, over 90% of transcripts in the mature human cortex include exon 18A. Early in fetal development, most transcripts include 18N or skip both 18N and 18A, with a transition to 18A inclusion occurring from 13 post-conceptual weeks to 6 months of age. No other protein-coding exons showed comparably dynamic developmental trajectories.

Significance: Splice isoforms, which alter the biophysical properties of the encoded channels, may account for some of the observed phenotypic differences across development and between specific variants. Manipulation of the proportion of splicing isoforms at appropriate stages of development may act as a therapeutic strategy for specific mutations or even epilepsy in general.

Keywords

isoform, splicing, epilepsy, neurodevelopmental disorders, *SCN1A*, *SCN2A*, *SCN3A*, *SCN8A*, 5A, 5N, 18A, 18N

1. Introduction

Genetic variation in the genes *SCN1A*, *SCN2A*, *SCN3A*, and *SCN8A* are a major cause of epileptic encephalopathy (EE), autism spectrum disorder (ASD), and developmental delay.^{1–3} These four homologous genes encode voltage-gated sodium channels (Nav1.1, Nav1.2, Nav1.3, and Nav1.6 respectively) that are critical for a range of functions in the central nervous system,⁴ including axonal action potential initiation and propagation,^{5,6} dendritic excitability,^{7,8} macroscopic anatomical development,⁹ and activity-dependent myelination.¹⁰ The functional role, subcellular location, expression-level, and isoform selection of voltage-gated sodium channels vary across development and understanding this relationship is critical for understanding the etiology of the associated disorders and their therapeutic management.^{7,11–19} While some isoform-level differences have been assayed in rodents and mature human brains,^{20–22} the trajectories in the developing human cortex have not been described.²³

Sodium channel genes are composed of multiple exons, which can be protein-coding (CDS for CoDing Sequence), untranslated regions (UTRs), or non-coding exons (NCEs). Differing combinations of these exons are called isoforms, which can change the amino acid sequence of the encoded proteins (proteoforms). The best-characterized isoform change across these four sodium channels are the two mutually exclusive copies of the fifth protein-coding exon.^{17,24} This exon encodes part of the first domain of the Nav channel, including the end of transmembrane segment S3, most of transmembrane segment S4, and a short extracellular linker connecting these two segments. In humans, each copy of this fifth protein-coding exon is 92 nucleotides in length, encoding 30 amino acids, of which one to three amino acids vary between the two exon copies for each gene (Fig. 1B). ‘A’ isoforms (5A) include the ancestral and canonical copy, with an aspartic acid residue (Asp/D) encoded at position 7 of 30.²⁵ ‘N’ isoforms (5N) use the alternative copy, with an asparagine (Asn/N) residue at position 7 of 30 in *SCN1A*, *SCN2A*, and *SCN8A* and a serine residue (Ser/S) in *SCN3A*. Despite this relatively small change in protein structure, differential inclusion of 5N or 5A can have marked effects on channel function. Indeed, these splice isoforms can alter channel electrophysiological characteristics,^{26,27} the functional impacts of variants associated with seizure,²³ neuronal excitability,²⁸ response to anti-epileptics,^{21,22,26} and seizure-susceptibility.²⁸

The utilization of the 5N or 5A varies across development, with 5N generally being expressed at higher levels in the neonatal period while 5A predominates in adults.²⁷ This switch is defined best in mouse, where the 5N:5A ratio varies by gene and brain region along with developmental stage.²⁰ For *Scn2a* in mouse neocortex, the 5N:5A ratio is 2:1 at birth (postnatal day 0/P0) and flips to 1:3 by P15. For both *Scn3a* and *Scn8a*, 5A predominates throughout the postnatal period with a 1:2 ratio at P0 increasing to 1:5 by P15.²⁰ *Scn1a* lacks a functional copy of 5N in the mouse genome. Similar developmental profiles currently have not been reported for humans beyond the of 5N/5A utilization *SCN1A* in adults, in which a 5N:5A ratio of over 1:5 was observed in the temporal cortex and hippocampus of adult surgical resections.^{21,22}

In addition to the 5N/5A switch, a similar developmental shift in mutually exclusive exons has been reported for “exons 18N or 18A” in *SCN8A* only, regulated by the RNA-binding protein RBFOX1.^{16,29,30} Using GENCODE human v31 gene definitions,³¹ 18A maps to the 20th protein-

coding exon of major *SCN8A* isoforms (CDS 20, Fig. 1A), while 18N encodes the 8th and last protein-coding exon (CDS 8) of a shorter eight protein-coding exon transcript (ENST00000548086.3, Fig. S1). In the embryonic mouse brain, most *SCN8A* transcripts include 18N or skip both 18N and 18A, leading to non-functional channels, while 18A predominates in the adult mouse and human brain.¹⁶

Here, we present data on the utilization of GENCODE-annotated protein-coding exons in four seizure-associated voltage-gated sodium channels in the human and mouse neocortex across development. We demonstrate a synchronized transition from 5N to 5A utilization between 24 post-conceptual weeks (2nd trimester) and six years-of-age across all four voltage-gated sodium channels and a transition from 18N to 18A in *SCN8A* from 13 post-conceptual weeks to 6 months-of-age. These isoform differences can modify the function of the encoded voltage-gated sodium channels, raising the potential that interventions, such as antisense oligonucleotides, could be used to modify the isoform ratio as a potential therapy for disorders caused by variants in sodium channel genes or epilepsy.

2. Materials and Methods

2.1 Genomic data

To quantify the relative proportion of protein-coding exon expression across development in the human cortex, we assessed bulk tissue RNA-seq data from 176 *post mortem* dorsolateral prefrontal cortex (DLPFC) samples from the BrainVar cohort.³² The BrainVar cohort also has corresponding whole-genome sequencing data that were used to derive per sample genotypes, as described previously.³² To assess corresponding patterns of exon expression in mouse cortex across development, we assessed 58 samples with bulk tissue RNA-seq data in wildtype C57/B6 mice. Thirty-four of these were generated as controls for ongoing experiments and 24 were downloaded from GEO.³³

2.2 Exon expression

To assess exon expression in the human cortex, the 100bp paired-read RNA-seq data from BrainVar were aligned to the GRCh38.p12 human genome using STAR aligner³⁴ and exon-level read counts for GENCODE v31 human gene definitions were calculated with DEXSeq³⁵ and normalized to counts per million (CPM).³⁶ Despite the similar amino acid sequence, the nucleotide sequence of 5N and 5A is sufficiently differentiated across the four genes that 100bp reads align unambiguously to one location in the genome.³⁷ Reads were detected in 5N and 5A for all samples, across all four genes, with the exception of the *SCN1A* for which 31 of 176 samples (17.6%) had no detectable 5N reads (Fig. 2A). Along with quantifying the expression of 5N and 5A (Fig. 2), we also assessed expression for the surrounding constitutive exons, as a control (Fig. S2). For the mouse cortical data, the same analysis methods were used but with alternative references, specifically the GRCm38/mm10 genome and GENCODE vM25 gene definitions. A similar approach was used to assess the utilization of 18N and 18A in *SCN8A*.

2.3 Intron splicing

We applied a complementary approach to detecting 5N and 5A exon usage by assessing intron splicing via reads that map across exon-exon junctions in the same 176 BrainVar samples. Reads were aligned with OLego aligner³⁸ using the same genome build and gene definitions as for exon expression. Clusters of differential intron splicing were identified with Leafcutter³⁹ and differences across development were detected by comparing 112 prenatal samples to 60 postnatal samples. No cluster was detected for 5N/5A in *SCN1A*, preventing assessment across development, but clusters were identified and assessed for the other three genes and for 18N/18A in *SCN8A* (Figs. 3, 5).

2.4 Quantitative trait locus (QTL) analysis

Common variants with a minor allele frequency $\geq 5\%$ in both the prenatal (N = 112) and postnatal (N = 60) samples and Hardy Weinberg equilibrium p value $\geq 1 \times 10^{-12}$ were identified previously.³² Variants within one million basepairs of each sodium channel gene were extracted and integrated with the Leafcutter clusters, along with the first five principal components calculated from common variants identified in whole-genome sequencing data from these samples and 3,804 parents from the Simons Simplex Collection^{32,40} to predict sQTLs with FastQTL.⁴¹ This analysis was performed on all samples, prenatal-only samples, and postnatal-

only samples, with false discovery rate (FDR) estimated from the results of each analysis using the Benjamini-Hochberg procedure.⁴² To assess correlation of 5N expression for the SNP rs3812718, genotypes were extracted for chr2:166,053,034 C>T (GRCh38) and compared with 5N expression calculated by DEXSeq, as described above.

2.5 Statistical analysis

The 5N:5A expression ratio was calculated from normalized exon expression values (CPM). Linear regression was used to assess whether this ratio varied across development by comparing the log-transformed 5N:5A ratio to log-transformed post-conceptual days (Fig. 2). The difference in ratio was also assessed between the mid-late fetal samples (N=112) and childhood/adolescent/young adult samples (N=35) with a two-tailed Wilcoxon test. To compare intron splicing between prenatal and postnatal samples, we used the P-values estimated with a Dirichlet-multinomial generalized linear model, as implemented in Leafcutter.³⁹

3. Results

3.1 Expression of voltage-gated sodium channels in the human cortex

Gene expression varies dramatically across development for many genes, especially during the late-fetal transition, during which half the genes expressed in the brains undergo a concerted increase or decrease in expression.^{12,32,43,44} To assess gene-level developmental trajectories, we analyzed bulk-tissue RNA-seq of the human DLPFC in 176 *post mortem* samples from the BrainVar cohort (104 male, 72 female, spanning 6 post-conceptual weeks to 20 years after birth).³² The gene-level expression profile of all four voltage-gated sodium channels changes during this late-fetal transition (Fig. 1F-I), with *SCN1A*, *SCN2A*, and *SCN8A* expression rising from mid-fetal development through infancy to early childhood, while *SCN3A* expression falls.

Figure 1. Splicing isoforms in voltage-gated sodium channels. **A)** Voltage-gated sodium channels are composed of four similar domains (I, II, III, IV), each of which includes six transmembrane segments with extracellular or intracellular linkers. The fourth transmembrane segment (S4) in each domain acts as a voltage sensor. Between the fifth and sixth transmembrane segment (S5, S6) is a pore loop that forms the ion selectivity filter. The fifth protein-coding exon (5N/5A, CDS 5) encodes a portion of the first domain, while the 20th protein-coding exon (18N/18A, CDS 20) encodes a similar portion of the third domain. **B)** Location, genomic coordinates (GRCh38/hg38), and amino acid sequence of the '5A' and '5N' exons four sodium channels. **C)** Patterns of whole-gene expression in the human dorsolateral prefrontal cortex (DLPFC) across prenatal and postnatal development from the BrainVar dataset ³². CPM: counts per million. Genomic coordinates are based on GRCh38/hg38 using GENCODE v31 gene definitions.

3.2 Developmental trajectories of 5N and 5A expression in the human cortex

The majority of protein-coding exons follow the expression trajectory of their parent gene across development (Fig. S3), however all four sodium channels show dynamic changes in the utilization of 5N/5A (Fig. 2). This is especially marked for *SCN2A* and *SCN8A*, where 5N is

expressed at a higher level than 5A in the mid-fetal brain but this reverses soon after birth. Plotting the 5N:5A ratio allows exon utilization to be assessed independent of changes in gene expression (Fig. 2). All four genes show changes in the N:A ratio across development, with a modest change for *SCN1A* (0.14 fetal to 0.02 childhood/adolescent; $p=0.00003$, two-sided Wilcoxon test, Figure 2B) and dramatic changes for *SCN2A* (3.7 to 0.09; $p=5 \times 10^{-19}$, Fig. 2D), *SCN3A* (0.96 to 0.18; $p=6 \times 10^{-18}$, Fig. 2F), and *SCN8A* (3.7 to 0.09; $p=5 \times 10^{-19}$, Fig. 2H). As a control, we applied this approach to assess the ratio of CDS 4 and CDS 6 across development. We observed no developmental shift in the 4:6 ratio for *SCN1A*, *SCN2A*, and *SCN3A*, however the exon 4:6 ratio is marginally higher than expected in the prenatal period for *SCN8A* (0.82 vs. 0.66; 9×10^{-10} , Fig. S2). This developmental variation in *SCN8A* is not observed for the surrounding protein-coding exons and reflects a modest increase in CDS 4 expression in the prenatal period, based on the expected expression given the exon length (Fig. S4).

Figure 2. Expression of 5N and 5A in the human cortex across development. **A)** The expression of 5N (blue) and 5A (red) in *SCN1A* is shown for 176 BrainVar human cortex (DLPFC) samples across development (points). On the left, the colored line shows the Loess smoothed average and 95% confidence interval (shaded region). On the right, boxplots show the median and interquartile range for the same data, binned into fetal, transitional, and mature developmental stages. **B)** The ratio of 5N and 5A expression from panel 'A' is shown across development (left) and in three developmental stages (right). **C-H)** Panels A and B are repeated for the genes *SCN2A*, *SCN3A*, *SCN8A*. For comparison, the same plots for CDS four and six are shown in Figure S2. CPM: Counts per million; DLPFC: Dorsolateral prefrontal cortex. Statistical tests: B, D, F, H) Left panel, linear regression of $\log_2(5N:5A \text{ ratio})$ and $\log_2(\text{post-conceptual days})$. Right panel, two-tailed Wilcoxon test of $\log_2(5N:5A \text{ ratio})$ values between fetal and mature groups.

3.3 Intron splicing around 5N and 5A in the human cortex

To verify that mutually exclusive use of 5N and 5A underlies the observed exon expression changes (Fig. 2), we considered RNA-seq reads that spanned exon-exon junctions to quantify intron splicing. Clusters of differential intron splicing corresponding to 5N/5A usage were identified by Leafcutter for *SCN2A*, *SCN3A*, and *SCN8A* (Fig. 3), but not *SCN1A*, likely due to the consistently low expression of N isoforms (Fig. 2). The splicing patterns for *SCN2A*, *SCN3A*, and *SCN8A* are consistent with the observed exon expression changes (Fig. 2, 3) and at least 99% of reads are consistent with mutually exclusive 5N/A utilization.

A ENSG00000136531 *SCN2A*

B ENSG00000153253 *SCN3A* (reversed)

C ENSG00000196876 *SCN8A*

Figure 3. Intron splicing of sodium channel genes in the developing human cortex. A) Sashimi plot of splicing in the prenatal (top, N=112 samples) and postnatal (bottom, N=60 samples) DLPFC for *SCN2A*. Linewidth is proportional to percentage of split reads observed for each intron and this value is given as a percentage. Introns related to 5N inclusion are shown in blue, those related to 5A inclusion are shown in red, and others are in grey. B-C) Equivalent plots for *SCN3A* (a negative strand gene with the orientation reversed to facilitate comparison to the other two genes) and *SCN8A*. P-values compare the prenatal and postnatal cluster using a Dirichlet-multinomial generalized linear model, as implemented in Leafcutter.³⁹

3.4 Developmental trajectories of 5N and 5A expression in the mouse cortex

We repeated the analysis of sodium channel 5N/5A expression using bulk tissue RNA-seq data from the mouse cortex across development (N=58; E15.5 to P75). Our data are consistent with the N:A ratios described previously.²⁰ We observe more substantial differences at the extremes of development: *SCN2A* (3.3 fetal to 0.06 mature; $p=0.00003$, two-sided Wilcoxon test, Fig. 4C),

SCN3A (2.4 to 0.14; $p=0.00008$, Fig. 4E), and *SCN8A* (1.8 to 0.22; $p=0.00003$, Fig. 4G). Mice lack a functional 5N exon in *SCN1A*.

Figure 4. Expression of 5N and 5A in the mouse cortex across development. **A)** The expression of 5A (red) in *Scn1a* is shown for 58 mouse cortex samples across development (points); no functional 5N equivalent is present in the mouse genome. On the left, the colored line shows the Loess smoothed average and 95% confidence interval (shaded region). On the right, boxplots show the median and interquartile range for the same data, binned into fetal, transitional, and mature developmental stages. **B)** The Loess smoothed average expression of the four voltage-gated sodium channels in human cortex (top, Fig. 1) and mouse cortex (bottom). **C)** Panel 'A' is repeated for *Scn2a* with the inclusion of 5N (blue). **D)** The ratio of 5N and 5A expression from panel 'C' is shown across development (left) and in three developmental stages (right). Values reported previously in mouse cortex are shown in the same scale in green for comparison²⁰. **E-H)** Panels 'C' and 'D' are repeated for the genes *Scn3a*, *Scn8a*.

CPM: Counts per million. Statistical tests: D, F, H) Left panel, linear regression of $\log_2(5N:5A \text{ ratio})$ and $\log_2(\text{post-conceptual days})$. Right panel, two-tailed Wilcoxon test of $\log_2(5N:5A \text{ ratio})$ values between fetal and mature groups.

3.5 No evidence of common polymorphisms regulating 5N or 5A utilization

A common polymorphism (rs3812718, GRCh38 chr2:166,053,034 C>T, IVS5N+5G>A) has previously been associated with epilepsy, seizures, and response to anti-epileptics,^{21,22,26,45,46} though this variant did not reach genome-wide significance in a mega-analysis of epilepsy.⁴⁷ Prior analyses of expression in the adult human temporal cortex showed evidence that the homozygous variant allele (TT in DNA, AA in cDNA) was associated with reduced utilization of 5N.^{21,48} We do not observe evidence for such a relationship in the prenatal or postnatal prefrontal cortex (Fig. S5) and this polymorphism is not identified as a splicing quantitative trait locus (QTL) in GTEx.⁴⁹ Furthermore, this variant is not predicted to alter splicing behavior using the SpliceAI algorithm.⁵⁰ The TT genotype is associated with increased expression of *SCN1A* in the adult human basal ganglia with ($p=1 \times 10^{-10}$).⁴⁹

3.6 Developmental trajectories of 18N and 18A expression in *SCN8A*

We next considered the developmental timing of the transition between 18N and 18A in *SCN8A* (Fig. 1A, 5A). Intron splicing shows a robust difference between prenatal and postnatal human dorsolateral prefrontal cortex ($P = 4 \times 10^{-185}$, Fig. 5B), with the prenatal period characterized by high frequencies of transcripts excluding 18A, either including 18N or skipping both 18N and 18A, while in the postnatal cortex 18A is included in 93% of reads. Considering exon expression (Fig. 5C, 5D), the expression of 18A increases markedly over development and this is distinct from other protein-coding exons for *SCN8A* (Fig. S3). The 18N/18A transition begins around 13 post-conceptual weeks and continues till six months-of-age, with both timepoints being earlier than the equivalents for 5N/5A in *SCN8A* and the other genes.

Figure 5. Developmental trajectories of CDS 20 (18N/18A) in human cortex in *SCN8A*. **A**) Location, genomic coordinates (GRCh38/hg38), and amino acid sequence of the 18N and 18A exons in *SCN8A*. **B**) Sashimi plot of intron splicing in the prenatal (top, N=112 samples) and postnatal (bottom, N=60 samples) dorsolateral prefrontal cortex. Linewidth is proportional to percentage of reads observed for each exon-exon junction and this value is also shown as a percentage. Introns related to 18N exon inclusion are shown in purple, those related to 18A exon inclusion are shown in green, and others are in grey. **C**)

Expression of the 18N (purple) and 18A (green) for 176 BrainVar human dorsolateral prefrontal cortex samples across development (points). On the left, the colored line shows the Loess smoothed average with the shaded area showing the 95% confidence interval. On the right, boxplots show the median and interquartile range for the same data, binned into fetal, transitional, and mature developmental stages. **D)** The 18N:18A ratio is shown for each sample from panel 'C' across development (left) and binned into three groups (right). CPM: Counts per million; Statistical analyses: B) Dirichlet-multinomial generalized linear model, as implemented in Leafcutter,³⁹ D) Left panel, linear regression of $\log_2(18N:18A \text{ ratio})$ and $\log_2(\text{post-conceptual days})$. Right panel, two-tailed Wilcoxon test of $\log_2(18N:18A \text{ ratio})$ values between fetal and mature groups.

3.7 Other annotated protein-coding exons with distinct developmental trajectories

To assess whether other protein-coding exons undergo distinct developmental transitions (Fig. S3), we calculated the ratios of all pairs of protein-coding exons within each for the four sodium channel genes and assessed whether the ratio was correlated with development stage using linear regression. This is the same calculation used to quantify the 5N/5A and 18N/18A transitions (Fig. 2, 5D) and distinguishes exons with expression profiles that differ from the rest of the gene (e.g. 5A in *SCN2A*), rather than simply being expressed at reduced levels, suggesting alternative regulatory processes (Fig. S3). Visualizing the R^2 values of these correlations provides simple method to identify the such distinct trajectories (Fig. 6). Aside from 5N/5A and, in *SCN8A*, 18N/18A, no protein-coding exons common to most isoforms (consistent CDS in Fig. S3) show differential expression, but a few weakly expressed protein-coding exons specific to a small number of isoforms (variable CDS in Fig. S3) do vary across development (Fig. 6).

GENCODE defines seven variable CDS exons for *SCN1A* (DEXSeq divisions: 006, 015, 021, 031, 034, 047, 049; Table S2, Fig. 6A). Of these, only 021 shows a distinct developmental trajectory (Fig. 6A), with reduced postnatal expression relative to other *SCN1A* exons (Fig. S3). This result is verified by the intron splicing data ($p = 6 \times 10^{-91}$, Leafcutter).

Figure 6. Identification of protein-coding exons with complex developmental trajectories. **A)** The correlation between the ratio of CPM expression between pairs of exons (log-scaled) and developmental stage (post conceptual days, log-scaled) for *SCN1A* was assessed with a linear model (e.g. Fig. 2B). The R^2 value of each exon pair is shown as a heat map with 'hot' colors representing exon-pairs with high R^2 values for which variation in the ratio is correlated with developmental age, i.e. pairs of exons that show substantially different expression across development. Exon numbers from DEXSeq (Table S2) are shown on the bottom and right and equivalent CDS number on the top and left (see Table S2). **B-D)** The analysis is repeated for *SCN2A*, *SCN3A*, and *SCN8A*.

In *SCN2A*, the 5N/5A trajectories stand out clearly (Fig. 6B). There are four variable CDS exons (DEXSeq divisions: 064, 079, 083, 087; Table S2, Fig. 6B), three of which have distinct developmental trajectories (Fig. 6B, S3): 064 (Fig. S3, $P = 2 \times 10^{-12}$, Leafcutter), 079 (Fig. S3, $P = 7 \times 10^{-33}$, Leafcutter), 087 (Fig. S3, $P = 2 \times 10^{-20}$, Leafcutter). The single variable CDS exon in *SCN3A*, 023 (Table S2, Fig. 6C), varies across development (Fig. S3, $P = 3 \times 10^{-80}$, Leafcutter). Finally, aside from 18N, there are five variable CDS exons in *SCN8A* (DEXSeq divisions: 018, 028,

029, 031, 039; Table S2, Fig. 6D) of which 018 and 029 vary across development (Fig. 6D), but neither of these are validated by Leafcutter.

Discussion

Using transcriptomic data from 176 human dorsolateral prefrontal cortex samples, we characterized the developmental patterns for all protein-coding exons in *SCN1A*, *SCN2A*, *SCN3A*, and *SCN8A* (Fig. 6, S3). We observed a coordinated decrease in the 5N:5A ratio between 24 post-conceptual weeks (2nd trimester) and six years-of-age that is synchronized with widespread transcriptomic changes in the brain during the late-fetal transition.^{32,44} This is preceded by a similar decrease in the 18N:18A ratio in *SCN8A* from 13 post-conceptual weeks to 6 months-of-age, which is regulated by *RBFOX1*. By analyzing a wider developmental window than prior analyses^{20,21,48} we observed more dynamic changes and larger disparities in exon expression.

Recent advances have shown that differential splicing patterns can be effective therapeutic targets in humans, for example through intrathecal antisense oligonucleotides.^{51,52} Since the electrophysiological consequences of some epileptic encephalopathy associated variants differ between 5N and 5A, manipulating this ratio may offer therapeutic benefit in individuals carrying these variants. We consider three therapeutic scenarios.

First, for individuals with disorder-associated genetic variants within the 30 amino acids encoded by the 5th exon, expressing the other copy of the 5th exon could skip the variant. Theoretically, this approach could benefit individuals with both loss-of-function (protein-truncating variants, missense, splice site) and gain-of-function (missense) variants in the 5th exon. At present, ten such cases have been identified, all with epileptic encephalopathy variants identified in the 5A exon of *SCN2A* and *SCN8A*.^{53,54} Since the total transcript level would be unchanged, this strategy may provide a wider therapeutic window than simply decreasing expression levels. The success of the therapy would depend upon the proportion of transcripts expressing the alternate 5th exon and the ability of this exon to functionally replace the original 5th exon.

Second, splice isoforms can also have an effect on the biophysical effects of variants outside the 5th exon. For example, three recently characterized epileptic encephalopathy associated variants in *SCN2A*—T236S, E999K, and S1336Y—all exhibit more pronounced alterations in their electrophysiological properties in 5N Nav1.2 isoforms.²³ Two other epileptic encephalopathy-associated variants—M252V and L1563V—exhibit biophysical changes only when expressed on 5N isoform.^{14,55} For individuals with these mutations, tilting expression towards the 5A isoform could provide some symptomatic improvement, especially during infancy. Including both the 5N and 5A isoforms in functional characterization of variant impact may identify many more such variants.²³

Finally, modifying splicing might aid seizure control in older children and adults. At this age, the 5A isoform is predominantly utilized in both *SCN2A* or *SCN8A*, which are mainly expressed in

glutamatergic neurons.¹¹ Reverting expression to the fetal/neonatal state by encouraging 5N utilization could reduce the excitability of cortical glutamatergic neurons, potentially limiting seizures. Since this would require repeated intrathecal administration, it would likely be limited to the most severe cases of epilepsy. Furthermore, it remains to be seen whether this approach could offer therapeutic benefits above and beyond existing antiepileptic drugs.

Our analysis was limited by the use of short-read transcriptomic data, leading us to focus on quantifying exon-level expression (Fig. 2) and splice junction usage (Fig. 3), rather than relying on estimates of isoform utilization (Fig. S1). We also elected to focus on protein-coding transcripts and exons defined by GENCODE (v31) rather than attempting *de novo* transcriptome assembly. Emerging long-read transcriptomic technology may substantially expand estimates of isoform and exon diversity but these technologies have not been applied to the developing human brain at scale.^{56,57} We also note that transcriptomic data is only partially predictive of protein levels and other factors, including channel transport and degradation, may influence the impact of isoforms on neuronal function. Comparing the human and mouse cortex data (Figs. 2, 4), it is possible that more substantial differences in gene and exon expression may be observed at earlier embryonic times in the mouse or with larger sample sizes. In addition, the use of bulk-tissue transcriptomic data limits our ability to assess how individual cell-types or cell-states contribute to the observed isoform trajectories. Technological and methodological advances may provide insights at cell-level resolution in the future.⁵⁸

Conclusion

Dramatic differences in exon usage of *SCN1A*, *SCN2A*, *SCN3A*, and *SCN8A* observed in rodent brains also occur in the human developing cortex, beginning in mid-fetal development and continuing through childhood. These changes in splicing affect the biophysical properties of the encoded channels and are likely to contribute to differences in phenotype observed between individuals with different variants and across development.

Acknowledgements

This work was supported by funding provided by the Simons Foundation Autism Research Initiative (SFARI) grants 574598 (to S.J.S.), 647371 (to S.J.S.), 629287 (to K.J.B.), and 513133 (to K.J.B.), the National Institute for Mental Health (NIMH) grants: R01 MH111662 (to S.J.S.), U01 MH122681 (to S.J.S.), P50 MH106934 (to N.S.), R01 MH109904 (to N.S.), R01 MH110926 (to N.S.), and U01 MH116488 (to N.S.), the National Institute of Neurological Disorders and Stroke (NINDS) grant: R01 NS099099 (to J.L.R.R.), and the National Research Foundation of Korea: NRF-2020R1C1C1003426 (to J.Y.A.) and NRF-2017M3C7A1026959 (to J.Y.A.).

Author Contributions

Experimental design, S.J.S.; Data generation, L.L., S.F.D., S.P., F.O.G., A.S., J.Y.A., and J.L.R.R.; Data processing, L.L., M.C.G., B.K.S., and D.M.W.; Data analysis, L.L., D.M.W., and S.J.S.; Statistical analysis, S.J.S.; Manuscript preparation, L.L., K.J.B., and S.J.S.

Declaration of interests

427 J.L.R.R. is cofounder, stockholder, and currently on the scientific board of *Neurona*, a company
428 studying the potential therapeutic use of interneuron transplantation.

References

1. Heyne HO, Singh T, Stamberger H, Abou Jamra R, Caglayan H, Craiu D, et al. De novo variants in neurodevelopmental disorders with epilepsy. *Nat Genet* [Internet]. 2018; :1. Available from: <http://www.nature.com/articles/s41588-018-0143-7>
2. Satterstrom FK, Kosmicki JA, Wang J, Breen MS, De Rubeis S, An J-Y, et al. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. *Cell*. 2020; .
3. Kaplanis J, Samocha KE, Wiel L, Zhang Z, Arvai KJ, Eberhardt RY, et al. Integrating healthcare and research genetic data empowers the discovery of 49 novel developmental disorders. *bioRxiv* [Internet]. 2019; :797787. Available from: <http://biorxiv.org/content/early/2019/10/16/797787.abstract>
4. Catterall WAWA, Marban E, Catterall WAWA, Cestèle S, Catterall WAWA, Wood JN, et al. Voltage-gated sodium channels. *J Physiol* [Internet]. 2001; 1(1):17–21. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3885250&tool=pmcentrez&rendertype=abstract%5Chttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3424717&tool=pmcentrez&rendertype=abstract%5Chttp://onlinelibrary.wiley.com/doi/10.1111/j.14>
5. Bender KJ, Trussell LO. The physiology of the axon initial segment. *Annu Rev Neurosci*. 2012; 35(1):249–65.
6. Kole MHP, Stuart GJ. Signal processing in the axon initial segment. *Neuron* [Internet]. 2012; 73(2):235–47. Available from: <http://dx.doi.org/10.1016/j.neuron.2012.01.007>
7. Spratt PWE, Ben-Shalom R, Keeshen CM, Burke KJJ, Clarkson RL, Sanders SJ, et al. The Autism-Associated Gene *Scn2a* Contributes to Dendritic Excitability and Synaptic Function in the Prefrontal Cortex. *Neuron*. 2019; 103(4):673-685.e5.
8. Hu W, Tian C, Li T, Yang M, Hou H, Shu Y. Distinct contributions of Na(v)1.6 and Na(v)1.2 in action potential initiation and backpropagation. *Nat Neurosci* [Internet]. 2009; 12(8):996–1002. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19633666>
9. Smith RS, Kenny CJ, Ganesh V, Jang A, Borges-Monroy R, Partlow JN, et al. Sodium Channel SCN3A (Na(V)1.3) Regulation of Human Cerebral Cortical Folding and Oral Motor Development. *Neuron*. 2018; 99(5):905-913.e7.
10. Berret E, Barron T, Xu J, Debner E, Kim EJ, Kim JH. Oligodendroglial excitability mediated by glutamatergic inputs and Nav1.2 activation. *Nat Commun* [Internet]. 2017; 8(1). Available from: <http://dx.doi.org/10.1038/s41467-017-00688-0>
11. Brunklaus A, Du J, Steckler F, Ghanty II, Johannesen KM, Fenger CD, et al. Biological concepts in human sodium channel epilepsies and their relevance in clinical practice. *Epilepsia*. 2020; 61(3):387–99.
12. Kang HJ, Kawasaki YI, Cheng F, Zhu Y, Xu X, Li M, et al. Spatio-temporal transcriptome of the human brain. *Nature* [Internet]. 2011; 478(7370):483–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22031440>

13. Wolff M, Johannesen KM, Hedrich UBS, Masnada S, Rubboli G, Gardella E, et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. *Brain* [Internet]. 2017; . Available from: <https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awx054>
14. Liao Y, Anttonen A-K, Liukkonen E, Gaily E, Maljevic S, Schubert S, et al. SCN2A mutation associated with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain. *Neurology*. 2010; 75(16):1454–8.
15. Tian C, Wang K, Ke W, Guo H, Shu Y. Molecular identity of axonal sodium channels in human cortical pyramidal cells. *Front Cell Neurosci* [Internet]. 2014; 8(September):297. Available from: <http://journal.frontiersin.org/article/10.3389/fncel.2014.00297/abstract>
16. Plummer NW, McBurney MW, Meisler MH. Alternative splicing of the sodium channel SCN8A predicts a truncated two-domain protein in fetal brain and non-neuronal cells. *J Biol Chem*. 1997; 272(38):24008–15.
17. Gustafson TA, Clevinger EC, Neill TJO, Yarowskys PJ, Krueger BK. Mutually exclusive exon splicing of type III brain sodium channel alpha subunit RNA generates developmentally regulated isoforms in rat brain. *J Biol Chem*. 1993; 268(25):18648–53.
18. Zaman T, Helbig KL, Clatot J, Thompson CH, Kang SK, Stouffs K, et al. SCN3A-Related Neurodevelopmental Disorder: A Spectrum of Epilepsy and Brain Malformation. *Ann Neurol*. 2020; .
19. Zaman T, Helbig I, Božović IB, DeBrosse SD, Bergqvist AC, Wallis K, et al. Mutations in SCN3A cause early infantile epileptic encephalopathy. *Ann Neurol*. 2018; 83(4):703–17.
20. Gazina E V, Richards KL, Mokhtar MBC, Thomas E a, Reid C a, Petrou S. Differential expression of exon 5 splice variants of sodium channel alpha subunit mRNAs in the developing mouse brain. *Neuroscience* [Internet]. 2010; 166(1):195–200. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20006674>
21. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. *Proc Natl Acad Sci U S A*. 2005; 102(15):5507–12.
22. Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. *Pharmacogenet Genomics*. 2006; 16(10):721–6.
23. Thompson CH, Ben-Shalom R, Bender KJ, George AL. Alternative splicing potentiates dysfunction of early-onset epileptic encephalopathy SCN2A variants. *J Gen Physiol*. 2020; 152(3):1–16.
24. Kasai N, Fukushima K, Ueki Y, Prasad S, Nosakowski J, Sugata KI, et al. Genomic structures of SCN2A and SCN3A - Candidate genes for deafness at the DFNA16 locus. *Gene*. 2001; 264(1):113–22.
25. Copley RR. Evolutionary convergence of alternative splicing in ion channels. *Trends Genet*. 2004; 20(4):171–6.

- 507 26. Thompson CH, Kahlig KM, George AL. SCN1A splice variants exhibit divergent sensitivity
508 to commonly used antiepileptic drugs. *Epilepsia*. 2011; 52(5):1000–9.
- 509 27. Diss JKJ, Fraser SP, Djamgoz MBA. Voltage-gated Na⁺ channels: Multiplicity of expression,
510 plasticity, functional implications and pathophysiological aspects. *Eur Biophys J*. 2004;
511 33(3):180–93.
- 512 28. Gazina E V., Leaw BTWW, Richards KL, Wimmer VC, Kim TH, Aumann TD, et al.
513 “Neonatal” Nav1.2 reduces neuronal excitability and affects seizure susceptibility and
514 behaviour. *Hum Mol Genet*. 2015; 24(5):1457–68.
- 515 29. O’Brien JE, Drews VL, Jones JM, Dugas JC, Barres BA, Meisler MH. Rbfox proteins regulate
516 alternative splicing of neuronal sodium channel SCN8A. *Mol Cell Neurosci* [Internet].
517 2012; 49(2):120–6. Available from: <http://dx.doi.org/10.1016/j.mcn.2011.10.005>
- 518 30. Zubović L, Baralle M, Baralle FE. Mutually exclusive splicing regulates the Nav 1.6 sodium
519 channel function through a combinatorial mechanism that involves three distinct splicing
520 regulatory elements and their ligands. *Nucleic Acids Res*. 2012; 40(13):6255–69.
- 521 31. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al.
522 GENCODE: the reference human genome annotation for The ENCODE Project. *Genome*
523 *Res* [Internet]. 2012; 22(9):1760–74. Available from:
524 <http://www.ncbi.nlm.nih.gov/pubmed/22955987>
- 525 32. Werling DM, Pochareddy S, Choi J, An J-YY, Sheppard B, Peng M, et al. Whole-Genome
526 and RNA Sequencing Reveal Variation and Transcriptomic Coordination in the Developing
527 Human Prefrontal Cortex. *Cell Rep*. 2020; 31(1):107489.
- 528 33. MacLaren R, Radcliffe RA, Van Matre ET, Robertson CE, Ir D, Frank DN. The Acute
529 Influence of Acid Suppression with Esomeprazole on Gastrointestinal Microbiota and
530 Brain Gene Expression Profiles in a Murine Model of Restraint Stress. *Neuroscience*
531 [Internet]. 2019; 398:206–17. Available from:
532 <https://doi.org/10.1016/j.neuroscience.2018.11.048>
- 533 34. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
534 universal RNA-seq aligner. *Bioinformatics*. 2013; 29(1):15–21.
- 535 35. Anders S, Reyes A, Huber W. Detecting differential usage of exons from RNA-seq data.
536 *Genome Res*. 2012; 22(10):2008–17.
- 537 36. Bedre R. renebedre/bioinfokit: Bioinformatics data analysis and visualization toolkit.
538 2020 [cited 2020]; . Available from:
539 <https://doi.org/10.5281/zenodo.3965241#.X1p62G7zZyE.mendeley>
- 540 37. Karimzadeh M, Ernst C, Kundaje A, Hoffman MM. Umap and Bismap: quantifying genome
541 and methylome mappability. *Nucleic Acids Res*. 2018; 46(20):e120.
- 542 38. Wu J, Anczukow O, Krainer AR, Zhang MQ, Zhang C. Olego: fast and sensitive mapping of
543 spliced mRNA-Seq reads using small seeds. *Nucleic Acids Res*. 2013; 41(10):5149–63.
- 544 39. Li YI, Knowles DA, Humphrey J, Barbeira AN, Dickinson SP, Im HK, et al. Annotation-free

quantification of RNA splicing using LeafCutter. *Nat Genet.* 2018; 50(1):151–8.

40. An J-Y, Lin K, Zhu L, Werling DM, Dong S, Brand H, et al. Genome-wide de novo risk score implicates promoter variation in autism spectrum disorder. *Science.* 2018; 362(6420):eaat6576.

41. Ongen H, Buil A, Brown AA, Dermitzakis ET, Delaneau O. Fast and efficient QTL mapper for thousands of molecular phenotypes. *Bioinformatics.* 2016; 32(10):1479–85.

42. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B.* 1995; 57(1):289–300.

43. Nowakowski TJ, Bhaduri A, Pollen AA, Alvarado B, Mostajo-Radji MA, Di Lullo E, et al. Spatiotemporal gene expression trajectories reveal developmental hierarchies of the human cortex. *Science [Internet].* 2017; 358(6368):1318–23. Available from: <http://www.sciencemag.org/lookup/doi/10.1126/science.aap8809>

44. Li M, Santpere G, Kawasawa YI, Evgrafov O V., Gulden FO, Pochareddy S, et al. Integrative functional genomic analysis of human brain development and neuropsychiatric risks. *Science.* 2018; 362(6420).

45. Tang L, Lu X, Tao Y, Zheng J, Zhao P, Li K, et al. SCN1A rs3812718 polymorphism and susceptibility to epilepsy with febrile seizures: a meta-analysis. *Gene.* 2014; 533(1):26–31.

46. Wang ZJ, Chen J, Chen HL, Zhang LY, Xu D, Jiang WT. Association between SCN1A polymorphism rs3812718 and valproic acid resistance in epilepsy children: a case-control study and meta-analysis. *Biosci Rep.* 2018; 38(6).

47. The International League Against Epilepsy Consortium on Complex Epilepsies. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. *Nat Commun.* 2018; 9(1):5269.

48. Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM, et al. Nova2 interacts with a Cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. *Am J Hum Genet.* 2007; 80(5):876–83.

49. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science [Internet].* 2015; 348(6235):648–60. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25954001>

50. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JFJF, Darbandi SFSF, Knowles D, Li YIYI, et al. Predicting Splicing from Primary Sequence with Deep Learning. *Cell [Internet].* 2019; 0(0):1–14. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0092867418316295>

51. Kim J, Hu C, Moufawad El Achkar C, Black LE, Douville J, Larson A, et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. *N Engl J Med.* 2019; 381(17):1644–52.

52. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen

- versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. *N Engl J Med* [Internet]. 2017/11/02. 2017; 377(18):1723–32. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/29091570>
53. Berkovic SF, Grinton B, Dixon-Salazar T, Laughlin BL, Lubbers L, Milder J, et al. De novo variants in the alternative exon 5 of SCN8A cause epileptic encephalopathy. *Genet Med*. 2018; 20(2):275–81.
54. Sanders SJ, Campbell AJ, Cottrell JR, Moller RS, Wagner FF, Auldridge AL, et al. Progress in Understanding and Treating SCN2A-Mediated Disorders. Vol. 41, *Trends in Neurosciences*. 2018. p. 442–56.
55. Xu R, Thomas EA, Jenkins M, Gazina E V., Chiu C, Heron SE, et al. A childhood epilepsy mutation reveals a role for developmentally regulated splicing of a sodium channel. *Mol Cell Neurosci*. 2007; 35(2):292–301.
56. Anvar SY, Allard G, Tseng E, Sheynkman GM, de Klerk E, Vermaat M, et al. Full-length mRNA sequencing uncovers a widespread coupling between transcription initiation and mRNA processing. *Genome Biol*. 2018; 19(1):1–18.
57. Clark MB, Wrzesinski T, Garcia AB, Hall NAL, Kleinman JE, Hyde T, et al. Long-read sequencing reveals the complex splicing profile of the psychiatric risk gene CACNA1C in human brain. *Mol Psychiatry* [Internet]. 2020; 25(1):37–47. Available from: <http://dx.doi.org/10.1038/s41380-019-0583-1>
58. Gupta I, Collier PG, Haase B, Mahfouz A, Joglekar A, Floyd T, et al. Single-cell isoform RNA sequencing characterizes isoforms in thousands of cerebellar cells. *Nat Biotechnol*. 2018; .
59. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*. 2010; 26(6):841–2.
60. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods*. 2017; 14(4):417–9.